Larimar Therapeutics LRMR
NASDAQ LRMR
$3.83 +0.00 (+0.00%)
At close: Sep 4, 2026 · 4:00 PM EDT

Larimar Therapeutics (LRMR) Prepaid Assets (2013 - 2026)

Larimar Therapeutics' (LRMR) quarterly Prepaid Assets came in at $4.4 million in Q2 2026, down 37.36% on a YoY basis from $7.0 million in Q2 2025, and down 14.8% quarter-over-quarter from $5.2 million in Q4 2025.

Analysis

Larimar Therapeutics (LRMR) Prepaid Assets (2013 - 2026) Analysis & Trends

Larimar Therapeutics (LRMR) has reported Prepaid Assets for 14 consecutive years, with $4.4 million the latest figure, recorded in Q2 2026.

  • For the quarter ending Q2 2026, Prepaid Assets fell 37.36% year-over-year to $4.4 million; the trailing twelve-month figure through Jun 2026 stood at $4.4 million (down 37.36% YoY), and the FY2025 full-year result was $5.2 million, down 56.37% from the prior year.
  • Prepaid Assets slipped to $4.4 million in Q2 2026 per LRMR's latest filing, from $5.2 million in the prior quarter.
  • Across five years, Prepaid Assets topped out at $11.8 million in Q4 2024 and bottomed at $1.8 million in Q2 2022.
  • Historically, Prepaid Assets has averaged $4.8 million across 5 years, with a median of $3.7 million in 2024.
  • The sharpest annual moves came in 2024 and 2025: Prepaid Assets jumped 250.07% in 2024, then tumbled 56.37% in 2025.
  • Over 5 years, Prepaid Assets stood at $2.3 million in 2022, then surged by 46.47% to $3.4 million in 2023, then surged by 250.07% to $11.8 million in 2024, then sank by 56.37% to $5.2 million in 2025, then dropped by 14.8% to $4.4 million in 2026.
  • According to Business Quant data, Prepaid Assets over the past three periods registered $4.4 million, $5.2 million, and $7.8 million for Q2 2026, Q4 2025, and Q3 2025 respectively.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Amgen 236.37 Bn 222.38 Bn 7.24 Bn
2 Gilead Sciences 187.38 Bn 184.12 Bn 6.22 Bn
3 Vertex Pharmaceuticals 138.36 Bn 130.51 Bn 2.84 Bn
4 Regeneron Pharmaceuticals 85.09 Bn 77.10 Bn 3.93 Bn
5 Argenx Se 63.93 Bn 58.75 Bn 1.37 Bn
6 Moderna 58.07 Bn 52.94 Bn 52.00 Mn
7 Alnylam Pharmaceuticals 35.59 Bn 32.28 Bn 992.69 Mn
8 Biogen 32.63 Bn 31.34 Bn 1.96 Bn
9 Insmed 27.57 Bn 26.41 Bn 358.27 Mn
10 Larimar Therapeutics 397.87 Mn 241.60 Mn -
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 4.41 Mn
Dec 31, 2025 5.17 Mn
Sep 30, 2025 7.79 Mn
Jun 30, 2025 7.03 Mn
Mar 31, 2025 7.96 Mn
Dec 31, 2024 11.85 Mn
Sep 30, 2024 9.55 Mn
Jun 30, 2024 5.07 Mn
Mar 31, 2024 3.66 Mn
Dec 31, 2023 3.39 Mn
Sep 30, 2023 2.89 Mn
Jun 30, 2023 2.28 Mn
Mar 31, 2023 1.94 Mn
Dec 31, 2022 2.31 Mn
Sep 30, 2022 2.43 Mn
Jun 30, 2022 1.82 Mn
Mar 31, 2022 2.32 Mn
Dec 31, 2021 2.11 Mn
Sep 30, 2021 3.23 Mn
Jun 30, 2021 3.41 Mn